Adverum soars on early gene therapy data; BerGenBio raises €45.4M on the heels of Covid-19 move
→ Another cut of positive interim data have lifted expectations that Adverum’s gene therapy that could give the anti-VEGF developers a run for their money in wet AMD. In a Phase I trial, investigators reported that the first two cohorts continue to respond to treatment, with the majority still free of rescue injections, while the third cohort experienced fewer side effects, presumably because they were given topical steroids rather than oral steroids.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
